Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Grand View Research | PRODUCT CODE: 1751231

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1751231

Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), By Application (Chronic Kidney Disease), By Region, And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2024 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost.
  • Iron sucrose held a significant share of the market in 2024. A low rate of severe allergic reactions has increased the adoption rate of these drugs.
  • The chronic kidney disease segment held the largest share in 2024, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases.
  • North America held the largest regional share in 2024 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD.
  • Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players.
Show more
Product Code: GVR-4-68038-000-2

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Intravenous Iron Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Intravenous Iron Drugs Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Iron Dextran
    • 4.4.1. Iron Dextran Market, 2018 - 2030 (USD Million)
  • 4.5. Iron Sucrose
    • 4.5.1. Iron Sucrose Market, 2018 - 2030 (USD Million)
  • 4.6. Ferric Carboxymaltose
    • 4.6.1. Ferric Carboxymaltose Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Iron Drugs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Chronic Kidney Disease
    • 5.4.1. Chronic Kidney Diseases Market, 2018 - 2030 (USD Million)
  • 5.5. Inflammatory Bowel Disease
    • 5.5.1. Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market, 2018 - 2030 (USD Million)
  • 5.7. Other Diseases
    • 5.7.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Iron Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Intravenous Iron Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AMAG Pharmaceuticals (Covis Pharma)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Daiichi Sankyo Company, Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Vifor Pharma Management Ltd. (CSL)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. PHARMACOSMOS A/S
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Zydus Group
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Rockwell Medical, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
Show more
Product Code: GVR-4-68038-000-2

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global intravenous iron drugs market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Global intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 8 North America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 9 U.S. intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 U.S. intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 11 Canada intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 13 Mexico intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Mexico intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 15 Europe intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Europe intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 18 UK intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 UK intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Germany intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 22 France intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 France intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 24 Italy intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Italy intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 26 Spain intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Spain intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 28 Norway intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Norway intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 30 Denmark intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 31 Denmark intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 32 Sweden intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 Sweden intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 37 Japan intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 38 Japan intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 39 China intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 40 China intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 41 India intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 42 India intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 43 Australia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 44 Australia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 45 South Korea intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 46 South Korea intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 47 Thailand intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Thailand intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 49 Latin America intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 51 Latin America intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 52 Brazil intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 53 Brazil intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 54 Argentina intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 55 Argentina intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Intravenous iron drugs market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 59 South Africa intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 60 South Africa intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 63 UAE intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 64 UAE intravenous iron drugs market, by application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait intravenous iron drugs market, by product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait intravenous iron drugs market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Intravenous iron drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Intravenous iron drugs market dynamics
  • Fig. 12 Intravenous iron drugs market: Porter's five forces analysis
  • Fig. 13 Intravenous iron drugs market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Iron Dextran market, 2018 - 2030 (USD Million)
  • Fig. 16 Iron Sucrose market, 2018 - 2030 (USD Million)
  • Fig. 17 Ferric Carboxymaltose market, 2018 - 2030 (USD Million)
  • Fig. 18 Others market, 2018 - 2030 (USD Million)
  • Fig. 19 Application market, 2018 - 2030 (USD Million)
  • Fig. 20 Chronic kidney disease market, 2018 - 2030 (USD Million)
  • Fig. 21 Inflammatory bowel disease market, 2018 - 2030 (USD Million)
  • Fig. 22 Cancer market, 2018 - 2030 (USD Million)
  • Fig. 23 Other Diseases market, 2018 - 2030 (USD Million)
  • Fig. 24 Intravenous iron drugs market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait intravenous iron drugs market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!